PsychopharmacologyAug 26, 2026

Ketamine’s effectiveness and side effects in moderate to severe obsessive-compulsive disorder

Psychedelic Science Weekly Brief ↗PubMed ↗DOI ↗

Updated Aug 27, 2026

Abstract

Approximately 40-60% of patients with obsessive-compulsive disorder (OCD) do not respond to standard treatments.

Ketamine is being evaluated for its potential effectiveness in treating moderate to severe OCD.
The review focuses on the efficacy, durability, and safety of ketamine as a treatment option.
Current treatments primarily involve serotonergic and behavioral therapies that do not work for many patients.

Simplified

Full Text

Full text is available at the source.

View Full Text ↗

Featured in

Psychedelic Science

Psychedelic ScienceIssue #53

One psilocybin session held antidepressant effects for 52 weeks in a new follow-up study

Weekly Psychedelic Science Brief

You found one interesting study. We’ll send the next 7.

Get 7 new psychedelic science papers each week, explained in plain English with direct links to the originals.

What Lands in Your Inbox Each Week:

📚7 fresh studies
📝plain-language summaries
✅direct links to original studies
🏅top journal indicators
📅weekly delivery
🧘‍♂️always free

Recent issues from the psychedelic science brief

One psilocybin session held antidepressant effects for 52 weeks in a new follow-up study

yesterday7 studies

Psilocybin didn't create disorder in the brain — it created a different kind of order

1 week ago7 studies

Psilocybin worked for treatment-resistant depression in real Swiss clinics — not just controlled trials

2 weeks ago7 studies

Psilocybin beat placebo on depression scores in an NHS trial — by a lot

3 weeks ago7 studies

Psilocybin stays active in neurons long after it leaves the bloodstream — here's what that means

4 weeks ago7 studies

Psychedelics during adolescence reshaped adult social behavior in rats — here's the circuit

5 weeks ago7 studies

Psilocybin rewired prefrontal circuits in mice — but only for one specific type of cognitive failure

6 weeks ago7 studies

Psilocybin cut two specific brain chemicals in depressed patients — here's what that means

7 weeks ago7 studies

Psilocybin rewires brain feedback circuits for weeks after a single dose, new evidence shows

8 weeks ago7 studies

A pill form of ketamine cut dissociation to near-zero vs. nasal spray's 29.6-point spike — but missed its main antidepressant target

9 weeks ago7 studies

explore the archive

See more issues from the psychedelic science brief